NCT04685915View on ClinicalTrials.gov

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 18, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2028

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Ibrutinib

Capsule, taken by mouth once daily

DRUG

Copanlisib

Intravenous Infusion

DRUG

Acalabrutinib

Capsule, taken by mouth twice daily

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Inhye Ahn

OTHER

NCT04685915 - Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | Biotech Hunter | Biotech Hunter